Renal impairment
Conditions
Interventions
test group :Take 4 ergothioneine capsules daily, two in the morning and two in the evening, for 90 consecutive days.
Sponsors
The First Affiliated Hospital of Anhui Medical University Clinical Research Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. 45=90 ml/min/(1.73 m^2) and urine albumin creatinine 30 mg/g =3 months; 4. Voluntarily sign the informed consent form before the start of activities related to this study, and be able to understand the procedures and methods of this study, and be willing to strictly comply with the clinical trial research protocol.
Exclusion criteria
Exclusion criteria: 1. Patients with abnormal liver function test results (AST or ALT or alkaline phosphatase >3ULN), or other known acute and chronic active hepatitis and cirrhosis; 2. Exclude people with poor drug control of hypertension, hyperlipidemia, hyperglycemia, and hyperuricemia; People with high risk and above criteria for diagnosis of chronic kidney disease are excluded. 3. Patients with nephritis have persistent hematuria, oliguria, anuria, generalized edema, or accompanied by hypertension or moderate or above proteinuria; 4. Those who use hormones or immunosuppressants due to kidney disease or kidney transplantation; 5. Patients with recurrent urinary tract infections or genital fungal infections before screening; 6. Patients with acute coronary syndrome, heart failure (NYHA score grade III-IV), or surgical treatment for heart-related diseases, stroke, or poor prognosis of stroke within 3 months before screening; 7. Those who have a history of mental illness or language impairment before screening and are unable or unwilling to cooperate; 8. History of autoimmune diseases (such as history of systemic lupus erythematosus, etc.) before screening; 9. History of gastrointestinal chronic diseases and surgical history that affect drug digestion, absorption, and metabolism before screening; 10. History of vaccine and drug abuse before screening; 11. Those who are participating in other drug clinical trials or have participated in other drug trials within 3 months before screening (referring to those who are enrolled and receive trial drug treatment); 12. Female patients who have a pregnancy plan, pregnancy or lactation within half a year; 13. Other conditions that the investigator judges are not suitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glomerular filtration rate;Urinary albumin-to-creatinine ratio;Renal function;8-Hydroxyuridine;Urine electrolyte levels;Voiding Diary; | — |
Countries
China
Contacts
Public ContactZhouHuan
The First Affiliated Hospital of Anhui Medical University Clinical Research Hospital
Outcome results
None listed